Genprex
Genprex is a clinical-stage, NASDAQ-listed gene therapy company developing REQORSA (TUSC2 lipid nanoparticle therapy) for non-small cell and small cell lung cancer and GPX-002 for diabetes, funded through equity financings with no commercial products or recurring revenue.
- Company typePublic
- Founded2009
- HeadquartersAustin, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genprex does
Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage biopharmaceutical company founded in 2009 (as Convergen LifeSciences, rebranded in September 2011) and headquartered in Austin, Texas. The company develops gene therapies for two distinct disease areas: oncology (with a primary focus on non-small cell lung cancer and extensive-stage small cell lung cancer) and diabetes (Type 1 and Type 2). Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid, formerly branded Oncoprex), encapsulates plasmid DNA encoding the TUSC2 tumor suppressor gene in the company's proprietary non-viral Oncoprex lipid nanoparticle delivery system, enabling systemic intravenous administration and repetitive dosing due to its non-immunogenic profile. REQORSA is being evaluated in three Phase 1/2 combination trials — Acclaim-1 (with AstraZeneca's Tagrisso for EGFR-mutant NSCLC), Acclaim-2 (with Merck's Keytruda for NSCLC), and Acclaim-3 (with Genentech's Tecentriq for ES-SCLC) — and has received FDA Fast Track Designations for both lung cancer programs plus Orphan Drug Designation for the SCLC program.
The underlying Oncoprex non-viral nanoparticle platform is the core technical asset, supported by patents granted or allowed in 12+ jurisdictions (US, Japan, Europe, Israel, Mexico, Russia, Chile, China, Singapore, Korea, Australia, Canada) covering REQORSA combinations with PD-1 and PD-L1 antibodies through 2037. A second product candidate, GPX-002 (Pdx1/MafA gene therapy licensed from the University of Pittsburgh), targets Type 1 and Type 2 diabetes via intrapancreatic infusion and is advancing toward an IND submission following an FDA meeting in Q1 2026. Manufacturing is supported by Aldevron (plasmid DNA supply) and a CDMO for GPX-002, with clinical operations conducted through academic medical centers including MD Anderson, University of Michigan, University of Kentucky, and Gabrail Cancer Center.
Genprex is pre-revenue with no commercially approved products and no disclosed recurring revenue. Its business model is future licensing/royalty income from combination development partnerships with large pharmaceutical companies and out-licensing of its patented delivery platform. Operations are funded through equity financings — including a 2018 IPO raising $6.4M and multiple subsequent registered direct offerings, most recently two October 2025 transactions totaling approximately $6.1M in primary proceeds (up to $18.2M with warrants). The company has 11-50 employees, a market capitalization of approximately $6.88M as of June 2026, and is navigating Nasdaq minimum bid price non-compliance following a reverse stock split on October 21, 2025.
Genprex firmographics
Firmographics- Name
- Genprex
- Legal name
- Genprex, Inc.
- Website
- https://genprex.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Genprex is a clinical-stage, NASDAQ-listed gene therapy company developing REQORSA (TUSC2 lipid nanoparticle therapy) for non-small cell and small cell lung cancer and GPX-002 for diabetes, funded through equity financings with no commercial products or recurring revenue.
- Ownership category
- akta.pro rank
Genprex industry classification
Industry- Product category
- Clinical-stage gene therapy biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Neurology/CNS Gene Therapies (HLAAACAH)
Keywords
Where Genprex is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Genprex business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Pre-Revenue Clinical Development: Genprex is a clinical-stage gene therapy company with no commercially approved products; no recurring product revenue. Operations funded primarily through equity financings (registered direct offerings, at-the-market offerings, private placements) and capital markets activity.
- Licensing and Partnership Income (Future): Genprex has licensed technologies and entered into combination development partnerships (e.g., University of Pittsburgh exclusive license for diabetes gene therapy; worldwide license for TUSC2+immunotherapy combinations); future potential licensing/royalty income from commercialized products developed with partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | No commercial products available; clinical-stage company with no pricing. |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Genprex product offering
Product offeringCore offering
Genprex is a clinical-stage gene therapy company developing investigational immunogene therapies that use its proprietary Oncoprex non-viral lipid nanoparticle delivery system to encapsulate therapeutic plasmid DNA. Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid), delivers the TUSC2 tumor suppressor gene and is being evaluated in Phase 1/2 trials for non-small cell lung cancer and small cell lung cancer in combination with approved targeted therapies and immunotherapies. The company is also developing GPX-002, a Pdx1/MafA gene therapy licensed from the University of Pittsburgh for Type 1 and Type 2 diabetes.
Product overview
Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company with a platform-plus-modules architecture anchored by its proprietary non-viral Oncoprex® Delivery System (a lipid nanoparticle platform that encapsulates and intravenously delivers therapeutic genes to tumor cells). On top of this delivery platform, Genprex develops a portfolio of gene therapy product candidates: its lead oncology candidate Reqorsa® Gene Therapy (quaratusugene ozeplasmid, formerly branded Oncoprex) targeting non-small cell and small cell lung cancer — evaluated across the Acclaim-1, Acclaim-2, and Acclaim-3 Phase 1/2 clinical trials in combination with Tagrisso, Keytruda, and Tecentriq respectively — and its diabetes candidate GPX-002 (a Pdx1/MafA gene therapy licensed from the University of Pittsburgh) being advanced under the DIA-001/DIA-002 preclinical programs toward an IND submission. The Oncoprex delivery platform underpins both product lines, enabling systemic, non-immunogenic, repeatable dosing of tumor suppressor and other disease-fighting genes.
Differentiator
Problem solved
Functional benefit
Brands
- Oncoprex® Delivery System: Proprietary non-viral nanoparticle delivery system used to administer Genprex's cancer-fighting genes.
- Reqorsa® Gene Therapy (quaratusugene ozeplasmid)
- GPX-002
Products and services
- Reqorsa Gene Therapy (quaratusugene ozeplasmid) Genprex's lead oncology drug candidate (formerly branded Oncoprex) is a TUSC2 gene therapy delivered via the Oncoprex non-viral nanoparticle delivery system, intended for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It has received FDA Fast Track Designation for both lung cancer programs and Orphan Drug Designation for the SCLC program, and is being evaluated in combination with AstraZeneca's Tagrisso (osimertinib) in Acclaim-1, Merck's Keytruda in Acclaim-2, and Genentech's Tecentriq (atezolizumab) in Acclaim-3 clinical trials.
- Oncoprex Delivery System Genprex's proprietary non-viral nanovesicle (lipid nanoparticle) delivery system that encapsulates disease-fighting genes and administers them intravenously for uptake by tumor cells. The nanovesicles are non-immunogenic, allowing repetitive therapeutic dosing, and have been clinically proven to selectively target primary and metastatic tumor cells while delivering therapeutic genes effectively.
- GPX-002 Genprex's diabetes gene therapy candidate based on a Pdx1/MafA gene construct, developed under an exclusive license from the University of Pittsburgh. It is being developed for both Type 1 and Type 2 diabetes using intrapancreatic infusion delivery (technically translatable to humans via endoscopic retrograde cholangiopancreatography). The therapy has shown preclinical proof-of-concept data in reversing hyperglycemia in mouse models and achieving normal glucose tolerance in non-human primates at four to seven months post-treatment.
Quantifiable outcome
- 79% tumor shrinkage when REQORSA combined with ALK inhibitor alectinib in ALK-EML4 NSCLC mouse models
- +5 more outcomes
Companies that use Genprex
Customer profileSegments4 records
Ideal customer profiles4 records
Genprex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Genprex partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered flagship, minor and core.
- The University of Texas MD Anderson Cancer CenterflagshipGenprex entered into a Sponsored Research Agreement with MD Anderson Cancer Center to study TROP2 and PTEN biomarkers that may predict patient response to Reqorsa Gene Therapy for NSCLC and SCLC. Research aims to refine patient selection strategies for Acclaim-1 and Acclaim-3 clinical trials. The collaboration builds on a relationship that began in 2010 and represents Genprex's continued commitment to precision oncology.
- University of KentuckyminorUniversity of Kentucky added as a clinical trial site for the Acclaim-3 Phase 2 study evaluating REQORSA in combination with Tecentriq as maintenance treatment for extensive stage small cell lung cancer patients, expanding patient enrollment.
- Gabrail Cancer CenterminorGenprex added Gabrail Cancer Center in Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 lung cancer gene therapy studies to expand enrollment and accelerate clinical research.
- University of PittsburghflagshipGenprex signed an exclusive license agreement with the University of Pittsburgh for a potentially curative diabetes gene therapy (GPX-002) that could treat Type 1 and Type 2 diabetes. The therapy was invented by Dr. George Gittes, Professor of Surgery at the Children's Hospital of Pittsburgh. Together the two diabetes types affect approximately 30.3 million people in the U.S.
- AldevroncoreAldevron supplies TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in Genprex's clinical development program evaluating Oncoprex immunogene therapy for NSCLC. The agreement establishes a GMP-validated supply of plasmid DNA vectors. Aldevron is a leading contract manufacturing organization based in Fargo, ND with facilities in Madison, WI, and Freiburg, Germany.
- AccenturecoreGenprex selected Accenture to provide clinical data management services to help accelerate the clinical development of Oncoprex immunogene therapy for NSCLC.
- University of Texas at Austin Dell Medical SchoolminorGenprex entered an agreement with The University of Texas at Austin Dell Medical School to establish executive offices at the school's Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab.
- AstraZeneca (Tagrisso/osimertinib)flagshipREQORSA is being evaluated in combination with AstraZeneca's Tagrisso (osimertinib) in the Acclaim-1 Phase 1/2 clinical trial for NSCLC patients with EGFR mutations. The combination received FDA Fast Track Designation.
- Genentech / Roche (Tecentriq/atezolizumab)flagshipREQORSA is being evaluated in combination with Genentech's Tecentriq (atezolizumab) as maintenance therapy for extensive stage small cell lung cancer in the Acclaim-3 Phase 1/2 clinical trial. The combination received FDA Fast Track Designation and Orphan Drug Designation.
- Merck (Keytruda/pembrolizumab)flagshipREQORSA Immunogene Therapy is being evaluated in combination with Merck's Keytruda in NSCLC patients with stage III or IV disease that progressed after Keytruda treatment. The combination received FDA Fast Track Designation.
- University of Michigan Rogel Cancer Center and ALK PositivecoreGenprex has partnered with the University of Michigan Rogel Cancer Center and ALK Positive (a non-profit patient-focused research group) for research on Reqorsa treatment for ALK-EML4 positive non-small cell lung cancer.
Scale indicators14 records
Recent moves10 records
Expansion highlights6 records
Genprex competitors and assessment
Company assessmentDirect peers
- Candel Therapeutics: Clinical-stage cancer gene therapy company developing oncolytic viral immunotherapies for solid tumors; directly comparable as a small-cap clinical-stage oncology gene therapy peer in lung cancer with similar FDA-designated programs and trial-stage economics.
- Precigen: Clinical-stage gene and cell therapy company with a non-viral UltraCAR-T platform and oncology focus including lung cancer programs; comparable as a gene therapy peer using non-viral delivery for solid tumors and hematologic malignancies.
- Ziopharm Oncology: Clinical-stage immuno-oncology and gene therapy company with non-viral Sleeping Beauty platform for CAR-T and TCR programs; directly comparable as a small clinical-stage gene therapy peer facing similar capital-constrained execution dynamics.
- Inovio Pharmaceuticals: Clinical-stage DNA medicine company developing DNA-based immunotherapies and gene therapies delivered via electroporation; directly comparable as a clinical-stage gene-based oncology peer with similar combination IO strategies.
- Gritstone bio: Clinical-stage immunotherapy company developing neoantigen-based cancer vaccines and gene-therapy-adjacent oncology approaches for lung cancer and other solid tumors; directly comparable as a clinical-stage IO gene therapy peer focused on checkpoint-resistant patients.
- Trizell (Japan Tobacco / Toray): Clinical-stage gene therapy company developing oncolytic virus and gene therapy for cancer including lung cancer indications; comparable as a clinical-stage oncology gene therapy peer with combination and intratumoral delivery approaches.
Emerging players
- Arcturus Therapeutics: Clinical-stage RNA medicines company using lipid nanoparticle delivery for vaccines and rare disease therapeutics; comparable as a lipid nanoparticle delivery peer for nucleic acid payloads, sharing platform-level delivery technology overlap with Genprex's Oncoprex system.
Broad incumbents
- BioNTech: Large oncology immunotherapy company with multiple cancer programs including mRNA-based and gene-therapy-adjacent approaches for solid tumors; broadly comparable as an incumbent IO player using nucleic acid platforms for cancer, though with vastly greater scale.
- Vertex Pharmaceuticals (VX-880 / cell therapy for diabetes): Large biopharma with a cell therapy program for Type 1 diabetes and broader gene-therapy-adjacent pipeline; comparable as an incumbent pursuing curative approaches in diabetes, overlapping with Genprex's GPX-002 therapeutic ambition.
- Moderna: Large mRNA and nucleic acid therapeutics company with oncology programs including checkpoint combinations and lipid nanoparticle delivery expertise; broadly comparable as an incumbent using LNP delivery for nucleic acid payloads into oncology indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Genprex social profiles
Digital presenceGenprex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genprex leadership team
Management profileNumber of profiles
Profiles4 records
Genprex subsidiaries and ownership
Company hierarchySubsidiaries1 record
Genprex funding detail
Funding detailFunding overview
Funding rounds12 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genprex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genprex
What does Genprex do?
Genprex is a clinical-stage gene therapy company developing investigational immunogene therapies that use its proprietary Oncoprex non-viral lipid nanoparticle delivery system to encapsulate therapeutic plasmid DNA. Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid), delivers the TUSC2 tumor suppressor gene and is being evaluated in Phase 1/2 trials for non-small cell lung cancer and small cell lung cancer in combination with approved targeted therapies and immunotherapies. The company is also developing GPX-002, a Pdx1/MafA gene therapy licensed from the University of Pittsburgh for Type 1 and Type 2 diabetes.
Is Genprex a public or private company?
Genprex is a public company. It is classified as public and is currently operating.
When was Genprex founded?
Genprex was founded in 2009. It employs 11 to 50 people.
Where is Genprex based?
Genprex is headquartered in Austin, United States, in the North America region.
How does Genprex make money?
Two revenue lines are on record. Pre-Revenue Clinical Development is the primary driver. The others are licensing and Partnership Income (Future).
Who are Genprex's main competitors?
Direct peers on record are Candel Therapeutics, Precigen, Ziopharm Oncology, Inovio Pharmaceuticals, Gritstone bio and Trizell (Japan Tobacco / Toray). Arcturus Therapeutics is listed as an emerging player. Broad incumbents are BioNTech, Vertex Pharmaceuticals (VX-880 / cell therapy for diabetes) and Moderna.
Does Genprex have an API?
No public API is recorded for Genprex.
What industry is Genprex in?
Genprex's product category is Clinical-stage gene therapy biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.